Vikram Purohit
Stock Analyst at Morgan Stanley
(0.76)
# 3,702
Out of 4,784 analysts
172
Total ratings
25.4%
Success rate
-14.44%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $60.60 | +7.26% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $118.53 | +60.30% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $8.17 | +328.40% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $3.52 | +155.68% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $19.90 | +55.78% | 2 | Sep 11, 2024 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $13 → $6 | $2.60 | +130.77% | 7 | Aug 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $59 → $64 | $63.84 | +0.25% | 6 | Aug 7, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $2.70 | +159.26% | 1 | Jul 3, 2024 | |
| ASND Ascendis Pharma | Maintains: Equal-Weight | $116 → $140 | $154.68 | -9.49% | 18 | May 16, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $6.43 | +148.83% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.94 | +920.41% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $8.28 | +165.70% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $15.73 | -36.43% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $1.21 | +395.87% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $7.83 | +436.40% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $5.81 | +89.33% | 1 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $1.18 | +1,806.78% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $29.62 | +38.42% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $18.08 | +121.24% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $0.91 | +1,328.57% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $19.96 | +90.38% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $9.91 | +101.82% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $9.23 | +8.34% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $28.98 | -75.85% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.35 | +1,529.63% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $6.20 | +222.58% | 2 | Aug 5, 2020 |
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $60.60
Upside: +7.26%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $118.53
Upside: +60.30%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $8.17
Upside: +328.40%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $3.52
Upside: +155.68%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $19.90
Upside: +55.78%
Acelyrin
Aug 19, 2024
Maintains: Equal-Weight
Price Target: $13 → $6
Current: $2.60
Upside: +130.77%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Overweight
Price Target: $59 → $64
Current: $63.84
Upside: +0.25%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $2.70
Upside: +159.26%
Ascendis Pharma
May 16, 2024
Maintains: Equal-Weight
Price Target: $116 → $140
Current: $154.68
Upside: -9.49%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $6.43
Upside: +148.83%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $2.94
Upside: +920.41%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $8.28
Upside: +165.70%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $15.73
Upside: -36.43%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $1.21
Upside: +395.87%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $7.83
Upside: +436.40%
Jul 13, 2023
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $5.81
Upside: +89.33%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $1.18
Upside: +1,806.78%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $29.62
Upside: +38.42%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $18.08
Upside: +121.24%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $0.91
Upside: +1,328.57%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $19.96
Upside: +90.38%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $9.91
Upside: +101.82%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $9.23
Upside: +8.34%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $28.98
Upside: -75.85%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.35
Upside: +1,529.63%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $6.20
Upside: +222.58%